Ginkgo Bioworks Holdings (DNA) Current Deferred Revenue (2019 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Current Deferred Revenue came in at $14.9 million in Q1 2026, down 55.69% YoY from $33.7 million in Q1 2025, and down 84.16% on a QoQ basis from $94.1 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Current Deferred Revenue (2019 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 8 years of Current Deferred Revenue data on file, last reported at $14.9 million in Q1 2026.
- Quarterly Current Deferred Revenue fell 55.69% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (down 55.69% YoY) and the FY2025 annual result came in at $94.1 million, down 25.61% from the prior year.
- Current Deferred Revenue fell to $14.9 million in Q1 2026, from $94.1 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $222.6 million in Q4 2022 to a low of $14.9 million in Q1 2026.
- A 5-year average of $80.3 million and a median of $42.8 million in 2023 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue jumped 368.98% — and 2024, when it slumped 80.56%.
- Tracing DNA's Current Deferred Revenue over 5 years: stood at $222.6 million in 2022, then declined by 9.03% to $202.5 million in 2023, then slumped by 37.53% to $126.5 million in 2024, then decreased by 25.61% to $94.1 million in 2025, then plunged by 84.16% to $14.9 million in 2026.
- The last three Current Deferred Revenue figures came in at $14.9 million (Q1 2026), $94.1 million (Q4 2025), and $25.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.21 Mn |
| Mar 31, 2026 | 14.91 Mn |
| Dec 31, 2025 | 94.10 Mn |
| Sep 30, 2025 | 25.24 Mn |
| Jun 30, 2025 | 28.29 Mn |
| Mar 31, 2025 | 33.65 Mn |
| Dec 31, 2024 | 126.50 Mn |
| Sep 30, 2024 | 22.89 Mn |
| Jun 30, 2024 | 26.01 Mn |
| Mar 31, 2024 | 33.61 Mn |
| Dec 31, 2023 | 202.50 Mn |
| Sep 30, 2023 | 42.76 Mn |
| Jun 30, 2023 | 133.78 Mn |
| Mar 31, 2023 | 139.27 Mn |
| Dec 31, 2022 | 222.60 Mn |
| Sep 30, 2022 | 139.05 Mn |
| Jun 30, 2022 | 45.50 Mn |
| Mar 31, 2022 | 35.23 Mn |
| Dec 31, 2021 | 189.20 Mn |
| Sep 30, 2021 | 29.65 Mn |